Dhanuka Agritech Limited has informed the Exchange that Board of Directors at its meeting held on May 16, 2025, recommended Final Dividend of Rs. 2 per equity share.
DHANUKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dhanuka Agritech's board approved audited standalone and consolidated results for Q4 and FY ended March 31, 2025, with statutory auditors S S Kothari Mehta & Co issuing an unmodified opinion. FY25 revenue from operations rose ~16% YoY to Rs. 2,035 crore, with profit before tax up ~23% to Rs. 392 crore and operating cash flow nearly doubling to Rs. 263 crore. Q4 alone delivered a strong performance, with revenue up ~20% to Rs. 442 crore and PAT of Rs. 75.5 crore, up ~28% YoY. The board recommended a final dividend of Rs. 2 per share (100% on face value) with a record date of July 18, 2025. Other key updates include the completed Rs. 100 crore buyback of 5 lakh shares, the acquisition of international rights to Iprovalicarb and Triadimenol from Bayer AG covering 20+ countries, and the cessation of Independent Director Mr. Siraz Azmat Chaudhary on July 22, 2025.
Strong full-year results, healthy operating cash flow expansion, and a 100% dividend signal financial strength and reward shareholders. The Bayer deal opens a new international growth runway across LATAM, EMEA and Asia, which could be a long-term positive, while the Rs. 100 crore buyback already executed supports EPS and signals capital discipline.